{"prompt": "['With the exception Herceptin IV dosing which should be modified for changes in body weight', '> 10%, study treatment doses should not be modified. No dose reductions are allowed for', 'Perjeta IV, Herceptin IV or pertuzumab and trastuzumab FDC SC. If an accidental overdose', 'or medication error occurs, it should be noted on the Study Drug Administration electronic', 'Case Report Form (eCRF). Cases of accidental overdose or medication error, along with', 'any associated AEs, should also be reported as described in Section 5.4.4.', 'Guidelines for treatment interruption or discontinuation for patients who experience AEs are', 'provided in Section 5.1.', '4.3.2.1', 'Pertuzumab and Trastuzumab FDC SC', 'Pertuzumab and trastuzumab FDC SC is given as a fixed dose (i.e. non-weight based). Two', 'doses of pertuzumab and trastuzumab FDC SC may be administered in the study: a 15 mL', 'loading dose consisting of 1200 mg pertuzumab and 600 mg trastuzumab and a 10 mL', 'maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Patients who', 'have had 6 weeks since their last neoadjuvant dose of Perjeta IV and Herceptin (IV or SC)', 'at study entry, or have had 6 weeks since their last study treatment during the study', 'treatment periods, must receive a loading dose before continuing with maintenance doses', 'for subsequent administrations.', 'All pertuzumab and trastuzumab FDC SC doses are administered by SC injection by the', 'investigator or their designee over 5 - 8 minutes at a rate of 2 mL/min with hand-held', 'syringe to the thigh on Day 1 of each 3-week treatment cycle. Patients should be monitored', 'for 30 minutes after their first pertuzumab and trastuzumab FDC SC dose administration', 'regardless of whether a loading dose is required. Patients should be monitored for 10 -', '15 minutes following subsequent administrations. Patients can be observed for longer', 'periods at the discretion of the investigator or if necessary, as per local requirements.', '4.3.2.2', 'Perjeta IV', 'Perjeta IV is administered at a dose of 840 mg (loading dose) or 420 mg (maintenance dose)', 'on Day 1 of each 3-week treatment cycle and should be administered prior to Herceptin IV.', 'Patients who have had 6 weeks since their last neoadjuvant dose of Perjeta IV at study', 'entry, or have had 6 weeks since their last study treatment during the study treatment', 'periods, must receive a loading dose before continuing with maintenance doses for', 'subsequent administrations.', 'Perjeta IV loading dose (if required) will be administered as a 60-minute infusion', '( 10 minutes), followed by an observation period of 60 minutes. If the loading dose infusion', 'is well tolerated, subsequent maintenance doses can be administered over a period of', '30 minutes ( 10 minutes) with an observation period of 30 minutes. Patients can be', 'observed for longer periods at the discretion of the investigator or if necessary, as per local', 'requirements. The observation period should be completed prior to the subsequent', 'Herceptin IV infusion.', '4.3.2.3', 'Herceptin IV', 'Herceptin IV is administered at a dose of 8 mg/kg (loading dose) or 6 mg/kg (maintenance', 'dose) on Day 1 of each 3-week treatment cycle and should be administered Perjeta IV', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '47 / Protocol MO40628, Version 12']['infusion and observation period are complete. Patients who have had 6 weeks since their', 'last neoadjuvant dose of Herceptin IV or Herceptin SC at study entry, or have had 6 weeks', 'since their last study treatment during the study treatment periods, must receive a loading', 'dose before continuing with maintenance doses for subsequent administrations.', 'Herceptin IV loading dose (if required) will be administered as an infusion over', 'approximately 90 ( 10) minutes after which the patient must be observed for 60 minutes. If', 'the loading dose is well tolerated, subsequent maintenance doses can be administered as', '30-minute infusions ( 10 minutes) followed by an observation period of 30 minutes. Patients', 'can be observed for longer periods at the discretion of the investigator or if necessary, as', 'per local requirements.', \"If variation in the patient's weight of + 10% compared with study baseline occurs, the\", 'Herceptin IV dose will be recalculated. Weight at the time the dose is recalculated will be', 'considered as baseline for subsequent evaluations of degree of weight change with respect', 'to Herceptin IV dose modification requirements.', '4.3.3', 'Investigational Medicinal Product Accountability', 'All IMPs required for completion of this study (pertuzumab and trastuzumab FDC SC,', 'Perjeta IV, Herceptin IV) will be provided by the Sponsor. The study site will acknowledge', 'receipt of IMPs supplied by the Sponsor. Any damaged shipments will be replaced.', \"IMPs will either be disposed of at the study site according to the study site's institutional\", \"standard operating procedure or be returned to the Sponsor for destruction. The site's\", 'method of destroying Sponsor-supplied IMPs must be agreed to by the Sponsor. The site', 'must obtain written authorization from the Sponsor before any Sponsor-supplied IMP is', 'destroyed, and IMP destruction must be documented on the appropriate form.', 'Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by', 'the study site should be recorded on the Drug Inventory Log.', '4.3.4', 'Continued Access to Pertuzumab and Trastuzumab FDC SC, Perjeta IV', 'and Herceptin IV', 'Due to the completion of the standard neo/adjuvant course of Herceptin plus Perjeta (18', 'cycles) within the trial, the Sponsor does not plan to provide the Roche IMPs (pertuzumab', 'and trastuzumab FDC SC, Perjeta IV, Herceptin IV) or any other study treatments or', 'interventions to patients who have completed the study.', '4.4', 'CONCOMITANT THERAPY', 'Concomitant therapy consists of any medication (e.g., prescription drugs, over-the-counter', 'drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a patient', 'from seven days prior to initiation of study drug until the End of Treatment Visit. After the', 'End of Treatment Visit and until the end of the study, only medications used for the', 'treatment of cancer will be reported. All such medications should be reported to the', 'investigator and recorded on the Concomitant Medications eCRF.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '48 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}